Literature DB >> 778308

Superinduction of interferon with metabolic inhibitors: possible mechanisms and practical applications.

J Vilcek, E A Havell, M Kohase.   

Abstract

Ten years have passed since cycloheximide was first shown to enhance endotoxin-induced production of interferon in mice, in the first demonstration of what was later called the superinduction of interferon. Various inhibitors of protein and RNA symthesis, as well as combinations of these inhibitors, have been shown to act as superinducing agents of interferon production stimulated by polyriboinosinic-polyribocytidylic acid. The evidence that superinduction is due to the suppression of a mechanism of post-transcriptional regulation of interferon synthesis is rather convincing. The notion (first proposed about six years ago) that this modification is caused by a protein "repressor" remains the most plausible, albeit still unproved, hypothesis. The availability of systems that translate with fidelity interferon messenger RNA isolated from induced cells should prove most useful in the elucidation of post-transcriptional control mechanisms of interferon synthesis and of interferon superinduction. Meanwhile, superinduction has become a useful tool for the production of large quantities of interferon. In particular, this technique has been successfully applied to the production of interferon from human diploid fibroblasts. The clinical potential of this material remains to be critically examined.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 778308     DOI: 10.1093/infdis/133.supplement_2.a22

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Interferon messenger RNA content of human fibroblasts during induction, shutoff, and superinduction of interferon production.

Authors:  P B Sehgal; B Dobberstein; I Tamm
Journal:  Proc Natl Acad Sci U S A       Date:  1977-08       Impact factor: 11.205

2.  Induction and decay of human fibroblast interferon mRNA.

Authors:  R L Cavalieri; E A Havell; J Vilcek; S Pestka
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

Review 3.  Antiviral agents: an update--Part 2.

Authors:  S Bogger-Goren; P L Ogra
Journal:  Indian J Pediatr       Date:  1980 Nov-Dec       Impact factor: 1.967

4.  Analysis of interferon mRNA in human fibroblast cells induced to produce interferon.

Authors:  N B Raj; P M Pitha
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

5.  Cell-produced viral inhibitor: possible mechanism of action and chemical composition.

Authors:  T K Hughes; J E Blalock; M L McKerlie; S Baron
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

6.  Kinetics of decay in the expression of interferon-dependent mRNAs responsible for resistance to virus.

Authors:  I Gordon; D Stevenson
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

7.  Interferon production in L929 cells under impaired translational conditions: comparison of rates of interferon, actin, Newcastle disease and encephalomyocarditis viruses mRNAs initiation of protein synthesis.

Authors:  V Sorrentino; A Battistini; P di Francesco; A M Curatola; G B Rossi
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

8.  Induction and regulation of mRNA encoding 26-kDa protein in human cell lines treated with recombinant human tumor necrosis factor.

Authors:  P Defilippi; P Poupart; J Tavernier; W Fiers; J Content
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

9.  Modified polyriboinosinic-polyribocytidylic acid complex: sustained interferonemia and its physiological associates in humans.

Authors:  K J Champney; D P Levine; H B Levy; A M Lerner
Journal:  Infect Immun       Date:  1979-09       Impact factor: 3.441

10.  Interferon induction with Newcastle disease virus in FS-4 cells: effect of 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB).

Authors:  M Kohase; J Vilcek
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.